Short answer
Vera Therapeutics, Inc. (VERA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$80M
- −72.2% YoY · −4.9% QoQ
- EPS (diluted)
- −$1.26
- −46.5% YoY · −5.0% QoQ
Source: XBRL data from the Vera Therapeutics, Inc. (VERA) Q3 2025 10-Q on SEC EDGAR. USD.
Vera Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factor this quarter; risks consistent with prior 10-K filing
- Material update on financing: $497.4M cash and marketable securities as of Sept 30, 2025, sufficient to fund operations beyond 12 months but capital needs remain high
- Regulatory risk: delays in clinical trials due to FDA disagreements, IRB issues, CRO performance, or manufacturing compliance could deeply impact approval timeline
- Operational risk: enrollment challenges in trials for IgAN due to patient identification difficulties and competitive trial recruitment environment
- Financial risk: $75.0M debt outstanding under 2025 Loan Agreement with $500M capacity; covenants may restrict operations and accelerate repayment upon default
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.